{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:59Z","timestamp":1793050979823,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,30]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Soluble B-cell maturation antigen (sBCMA) is elevated on multiple myeloma (MM) cells. We investigated whether sBCMA levels correlated with other myeloma tumor volume indicators and its utility in monitoring oligosecretory\/nonsecretory (O-S\/Non-S) MM. In 115 patients with newly diagnosed MM, sBCMA was compared with M-protein levels, bone marrow plasma cells (BMPCs), circulating tumor cells (CTCs), and total diffusion volume (tDV; estimated by whole-body diffusion-weighted magnetic resonance imaging) at diagnosis. sBCMA levels increased significantly with International Staging System stage, chromosome 1q21 gain\/amplification, and CTC levels. sBCMA also correlated strongly with %BMPC (r\u00a0=\u00a00.65) and moderately with tDV (r\u00a0=\u00a00.55) and paraprotein levels (involved immunoglobulin in IgG and IgA subtypes, r\u00a0=\u00a00.44 and 0.4; involved free light-chain levels in light-chain-only MM, r\u00a0=\u00a00.61, all P\u00a0&amp;lt; .05). Longitudinal changes in sBCMA were consistent with disease status in both 17 O-S\/Non-S and other secretory MM cases. Furthermore, sBCMA levels increased as early as 6 months prerelapse in almost all O-S\/Non-S relapsed patients. Thus, sBCMA correlates strongly with total tumor volume in MM, as assessed using different modalities. We suggest that sBCMA is useful, not only for monitoring responses in patients with O-S\/Non-S MM but also for early relapse detection and prediction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026028","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:57:07Z","timestamp":1729706227000},"page":"526-532","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-4616","authenticated-orcid":false,"given":"Daisuke","family":"Ikeda","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Aikawa","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Misono","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-4647","authenticated-orcid":false,"given":"Mitsuaki","family":"Oura","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9641-3602","authenticated-orcid":false,"given":"Fuminari","family":"Fujii","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Sakuma","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5823-8395","authenticated-orcid":false,"given":"Masanori","family":"Toho","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5350-4316","authenticated-orcid":false,"given":"Atsushi","family":"Uehara","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-9046","authenticated-orcid":false,"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-8356","authenticated-orcid":false,"given":"Tomohisa","family":"Watari","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Otsuka","sequence":"additional","affiliation":[{"name":"2Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-9865","authenticated-orcid":false,"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025013016203720900_bib1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMc1206740","article-title":"Prevalence and monitoring of oligosecretory myeloma","volume":"367","author":"Larson","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"2025013016203720900_bib2","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1182\/blood-2021-151255","article-title":"Multiple myeloma oligosecretory relapse, a non-negligible phenomenon. frequency, clinical characteristics and outcomes in a single center","volume":"138","author":"Zamir","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2025013016203720900_bib3","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025013016203720900_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell maturation antigen in multiple myeloma","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"issue":"19","key":"2025013016203720900_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025013016203720900_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2025013016203720900_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"2025013016203720900_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025013016203720900_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13666","article-title":"Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma","volume":"107","author":"Bujarski","year":"2021","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025013016203720900_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","article-title":"Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed\/refractory multiple myeloma starting new therapy","volume":"16","author":"Bujarski","year":"2021","journal-title":"Target Oncol"},{"issue":"2","key":"2025013016203720900_bib11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjh.16752","article-title":"Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment","volume":"192","author":"Jew","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"2025013016203720900_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025013016203720900_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025013016203720900_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"key":"2025013016203720900_bib15","doi-asserted-by":"crossref","first-page":"1611171","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"2025013016203720900_bib16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bjh.16673","article-title":"Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients","volume":"192","author":"Jew","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025013016203720900_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/bloodadvances.2023011890","article-title":"Analysis of baseline circulating tumor cells integrated with PET\/CT findings in transplant-ineligible multiple myeloma","volume":"8","author":"Ikeda","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2025013016203720900_bib18","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1007\/s00330-021-07687-2","article-title":"Total diffusion volume in MRI vs. total lesion glycolysis in PET\/CT for tumor volume evaluation of multiple myeloma","volume":"31","author":"Terao","year":"2021","journal-title":"Eur Radiol"},{"issue":"1","key":"2025013016203720900_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-024-00986-z","article-title":"Genome-wide CRISPR\/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells","volume":"14","author":"Ajore","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025013016203720900_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.5858\/2007-131-951-QOPCIB","article-title":"Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment","volume":"131","author":"Smock","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2025013016203720900_bib21","doi-asserted-by":"crossref","first-page":"e0229607","DOI":"10.1371\/journal.pone.0229607","article-title":"Assessment of early treatment response on MRI in multiple myeloma: comparative study of whole-body diffusion-weighted and lumbar spinal MRI","volume":"15","author":"Takasu","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"2025013016203720900_bib22","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ajh.27414","article-title":"Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma","volume":"99","author":"Kostopoulos","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"2025013016203720900_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025013016203720900_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2009.07952.x","article-title":"Frequency of altered monoclonal protein production at relapse of multiple myeloma","volume":"148","author":"Hobbs","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2025013016203720900_bib25","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining nonmeasurable multiple myeloma using mass spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/526\/2353514\/blood_bld-2024-026028-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/5\/526\/2353514\/blood_bld-2024-026028-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:20:50Z","timestamp":1738254050000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/5\/526\/518299\/Soluble-B-cell-maturation-antigen-levels-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,1,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026028","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}